User profiles for Sara Y. Tartof
 | Sara TartofEpidemiologist/Research Scientist, Kaiser Permanente Southern California Department of … Verified email at kp.org Cited by 6247 |
[HTML][HTML] Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2)
variant and potential waning immunity in observed reductions in effectiveness against …
variant and potential waning immunity in observed reductions in effectiveness against …
[HTML][HTML] Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients
Objectives To compare hospitalisation rates, intensive care unit (ICU) admissions and
mortality for patients with COVID-19 who were consistently inactive, doing some activity or …
mortality for patients with COVID-19 who were consistently inactive, doing some activity or …
[HTML][HTML] Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1. 529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California
Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-19)
hospitalizations and deaths from case counts after emergence of the Omicron (B.1.1.529…
hospitalizations and deaths from case counts after emergence of the Omicron (B.1.1.529…
Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization
SY Tartof, L Qian, V Hong, R Wei… - Annals of internal …, 2020 - acpjournals.org
Background: Obesity, race/ethnicity, and other correlated characteristics have emerged as
high-profile risk factors for adverse coronavirus disease 2019 (COVID-19)–associated …
high-profile risk factors for adverse coronavirus disease 2019 (COVID-19)–associated …
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a …
SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet …, 2022 - thelancet.com
Background The duration of protection against the omicron (B.1.1.529) variant for current
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed…
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed…
Clinical outcomes among patients infected with Omicron (B. 1.1. 529) SARS-CoV-2 variant in southern California
Background The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global
dissemination, accounting for most infections in the United States by December 2021. Risk of …
dissemination, accounting for most infections in the United States by December 2021. Risk of …
Analysis of a Uropathogenic Escherichia coli Clonal Group by Multilocus Sequence Typing
SY Tartof, OD Solberg, AR Manges… - Journal of clinical …, 2005 - Am Soc Microbiol
Although many strain typing methods exist for pathogenic Escherichia coli, most have
drawbacks in terms of resolving power, interpretability, or scalability. For this reason, multilocus …
drawbacks in terms of resolving power, interpretability, or scalability. For this reason, multilocus …
Waning immunity to pertussis following 5 doses of DTaP
SY Tartof, M Lewis, C Kenyon, K White, A Osborn… - …, 2013 - publications.aap.org
OBJECTIVE: To assess the risk of pertussis by time since vaccination in children in Minnesota
and Oregon who received 5 doses of acellular pertussis vaccines (DTaP). METHODS: …
and Oregon who received 5 doses of acellular pertussis vaccines (DTaP). METHODS: …
Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases
A Langer-Gould, L Qian, SY Tartof, SM Brara… - JAMA …, 2014 - jamanetwork.com
Importance Because vaccinations are common, even a small increased risk of multiple
sclerosis (MS) or other acquired central nervous system demyelinating syndromes (CNS ADS) …
sclerosis (MS) or other acquired central nervous system demyelinating syndromes (CNS ADS) …
[HTML][HTML] Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study
SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet Regional …, 2022 - thelancet.com
Background Globally, recommendations are expanding for third (booster) doses of
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …